Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
| Status: | Completed |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - 90 |
| Updated: | 11/23/2013 |
| Start Date: | July 2011 |
| End Date: | October 2014 |
| Contact: | Pfizer CT.gov Call Center |
| Phone: | 1-800-718-1021 |
A Multicenter, Open-label Extension, Multiple-dose, Parallel Group Study to Investigate the Long-term Safety and Tolerability of AAB-003 (PF-05236812) Administered Intravenously in Subjects With Mild to Moderate Alzheimer's Disease Previously Treated With AAB-003 or Placebo in Protocol B2601001
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003
(PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete
study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each
patient's participation will last approximately 52 weeks.
Inclusion Criteria:
- Successful completion of study B2601001
- MMSE 12 or greater
Exclusion Criteria:
- Study B2601001 Week 32 MRI with clinically important exclusionary findings.
- Experienced SAE, vasogenic edema and/or intracranial hemorrhage in study B2601001
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials